Table 2. Characteristics of patients in SAP group and non-SAP group.
| Characteristics | SAP (n, %) | N- SAP (n, %) | P-value |
| Gender | 0.716 | ||
| Male | 63 (52.1) | 21 (48.8) | |
| Female | 58 (47.9) | 22 (51.2) | |
| Age (years old) | 0.251 | ||
| <40 | 65 (53.7) | 31 (72.1) | |
| ≥40 | 56 (46.3) | 12 (27.9) | |
| Underlying disease | 1.000 | ||
| Acute leukemia | 109 (90.1) | 39 (90.7) | |
| Others | 12 (9.9) | 4 (9.3) | |
| Disease stage | 0.081 | ||
| Low-risk stage | 80 (66.1) | 22 (51.2) | |
| High-risk stage | 41 (33.9) | 21 (48.8) | |
| Disease treatment | 0.257 | ||
| Chemotherapy/auto-HSCT | 61 (50.4) | 26 (60.5) | |
| Allo-HSCT | 60 (49.6) | 17 (39.5) | |
| Use of corticosteroid * | 0.974 | ||
| Yes | 51 (42.1) | 18 (41.9) | |
| No | 70 (57.9) | 25 (58.1) | |
| Duration of neutropenia | 0.838 | ||
| <14 d | 71 (58.7) | 26 (60.5) | |
| ≥14 d | 50 (41.3) | 17 (39.5) | |
| Conditioning regimens | 0.880 | ||
| With TBI | 20 (33.3) | 6 (35.3) | |
| Without TBI | 40 (66.7) | 11 (64.7) | |
| Conditioning regimens | 0.926 | ||
| With ATG | 31 (51.7) | 9 (52.9) | |
| Without ATG | 29 (48.3) | 8 (47.1) | |
| Conditioning regimens | 0.674 | ||
| MAC | 52 (86.7) | 16 (94.1) | |
| RIC | 8 (13.3) | 1 (5.9) | |
| Acute GVHD | 0.761 | ||
| Presence | 20 (33.3) | 5 (29.4) | |
| Absence | 40 (66.7) | 12 (70.6) | |
| Chronic GVHD | 0.819 | ||
| Presence | 23 (38.3) | 6 (35.3) | |
| Absence | 37 (61.7) | 11 (64.7) | |
| CMV DNAemia [16] | 0.880 | ||
| Presence | 33 (55.0) | 9 (52.9) | |
| Absence | 27 (45.0) | 8 (47.1) | |
| Diagnosis of previous IFD | 0.072 | ||
| Proven | 15 (12.4) | 1 (2.3) | |
| Probable | 106 (87.6) | 42 (97.7) |
SAP, secondary antifungal prophylaxis; auto-HSCT, autologous hematopoietic stem cell transplantation; allo-HSCT, allogeneic hematopoietic stem cell transplantation; TBI, total body irradiation; ATG, antithymocyte globulin; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; GVHD, graft-versus-host-disease; CMV, cytomegalovirus; IFD, invasive fungal disease.
*corticosteroid was defined as 1 mg/kg or 2 mg/kg for more than 3 weeks for the treatment of acute lymphoblastic leukemia or for the management of GVHD before IFD.